Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 12, 2010, Pages 847-853

  Ma, J D ^a   Nguyen, E T ^a   Tsunoda, S M ^a   Greenberg, H E ^b   Gorski, J C ^c   Penzak, S R ^d   Lee, L S ^e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Clinilabs   (United States)

^c Formulation Development Services   (India)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NONE

Author keywords

CYP3A; Limited sampling strategy; Midazolam; Phenotyping

Indexed keywords

CYTOCHROME P450 3A; GINKGO BILOBA EXTRACT; KETOCONAZOLE; MIDAZOLAM; PLECONARIL; RIFAMPICIN;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SCREENING; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; LIMITED SAMPLING STRATEGY; MATHEMATICAL ANALYSIS; NORMAL HUMAN; PREDICTION; PROTEIN FUNCTION; PROTEIN INDUCTION; SAMPLING ERROR; VALIDATION PROCESS;

EID: 78650804394     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48847     Document Type: Article

References (31)

1. Al-Khatib M, Shapiro RJ, Partovi N, Ting LSL, Levine M, Ensom MHH. Limited sampling strategies for predicting area under the concentration-time curve of mycophenolic acid in islet transplant recipients. Ann Pharmacother. 2010; 44: 19-27.
2. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther. 1981; 30: 653-661.
3. Backman JT, Olkkoa KT, Neuvonen P. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996; 59: 7-13. (Pubitemid 26046768)
4. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003; 43: 443-469.
5. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase, and xanthine oxidase activities with the "Cooperstown 5+1" cocktail. Clin Pharmacol Ther. 2003; 74: 437-447.
6. Chaobal HN, Kharasch ED. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther. 2005; 78: 529-539.
7. Chung E, Nafziger AN, Kazierad DJ, Bertino JS. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther. 2006; 79: 350-361.
8. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R. Oral administration of a low dose of midazolam (75 mcg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol. 2004; 60: 237-246.
9. Eap CB, Fellay J, Buclin T, Bleiber G, Golay KP, Brocard M, Baumann P, Telenti A. CYP3 Aactivity measured by the midazolam test is not related to 3435 C > T polymorphism in the multiple drug resistance transporter gene. Pharmacogenetics. 2004; 14: 255-260.
10. Gorski JC, Hall SD, Jones DR, Vanderbranden M, Wrighton S. Midazolam metabolism to 4-OH midazolam and 1-OH midazolam by human cytochrome P450 3A. Clin Pharmacol Ther. 1993; 53: 188.
11. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner BD, Hall SD. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003; 74: 275-287.
12. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999; 20: 342-349.
13. Kim JS, Nafziger AN, Tsunoda SM, Choo EF, Streetman DS, Kashuba ADM, Kulawy RW, Beck DJ, Rocci ML, Wilkinson GR, Greenblatt DJ, Bertino JS. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol. 2002; 42: 376-382.
14. Kupferschmidt HT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995; 58: 20-28.
15. Lee LS, Bertino JS, Nafziger AN. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J Clin Pharmacol. 2006; 46: 229-234.
16. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED, Thummel KE. Invivo phenotyping for CYP3Aby a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001; 11: 781-791.
17. Ma JD, Nafziger AN, Kashuba ADM, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predict S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol. 2004; 44: 570-576.
18. Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metabolism and Disposition. 2006; 34: 783-785.
19. Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol. 2006; 46: 103-108.
20. Mahmood I. Development of a limited sampling approach in pharmacokinetic studies: experience with the antiepilepsy drug tiagabine. J Clin Pharmacol. 1998; 38: 324-330.
21. Mahmood I. Center specificity in the limited sampling model (LSM): can the LSM developed from healthy subjects be extended to disease states? Int J Clin Pharmacol Ther. 2003; 41: 517-523.
22. Penzak SR, Busse KH, Robertson SM, Formentini E, Alfaro RM, Davey RT. Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharmacol. 2008; 48: 671-680.
23. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy adults. Curr Med Res Opin. 2008; 24: 591-599.
24. Rogers JF, Nafziger AN, Bertino JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002; 113: 746-750.
25. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981; 9: 503-512.
26. Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000; 10: 187-216.
27. Tham LS, Lee HS, Wang L, Yong WP, Fan L, Ong AB, Sukri NM, Soo R, Lee SC, Goh BC. Ketoconazole renders poor CYP3A phenotype status with midazolam as a probe drug. Ther Drug Monit. 2006; 28: 255-261.
28. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999; 66: 461-471.
29. Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauch WW, Pequignot E, Waldman SA, Greenberg HE. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol. 2003; 43: 831-839.
30. Wu G. Calculating predictive performance: a user's note. Pharm Res. 1995; 31: 393-399.
31. Zhu B, Ou-Yang DS, Cheng ZN, Huang SL, Zhou HH. Single plasma sampling to predict oral clearance of CYP3Aprobe midazolam. Acta Pharmacol Sin. 2001; 22: 634-638.